Selective Serotonin Reuptake Inhibitor Treatment in Adolescence and Subsequent Risk of Nonaffective Psychosis: A Quasi‐Experimental Study
Acta Psychiatrica Scandinavica · 2026-08 · 154 (2) · 153-162
DOI: 10.1111/acps.70098 ↗Kurz gefasst
Fachartikel in der Zeitschrift Acta Psychiatrica Scandinavica, online erschienen am 07.04.2026. Verfasst von Ioanna Kougianou und 4 weiteren Autor:innen. Beteiligte Einrichtung: Division of Psychiatry, Institute for Neuroscience and Cardiovascular Research, University of Edinburgh, Edinburgh, UK. Hauptthemen laut MEDLINE: Selective Serotonin Reuptake Inhibitors, Psychotic Disorders, Depressive Disorder. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 43 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Department for Business, Energy and Industrial Strategy, UK Government, Health Research Board, Academy of Medical Sciences.
Abstract (Originalsprache)
Objective
Psychotic disorders are frequently preceded by common mental disorders (CMDs), like depression and anxiety. It remains unclear whether treating CMDs in adolescence can reduce subsequent psychosis risk. We applied quasi‐experimental methods to national register data to assess whether a causal relationship exists between selective serotonin reuptake inhibitor (SSRI) treatment in adolescence and subsequent risk of psychosis.
Methods
Using the secure anonymized information linkage databank, we identified individuals living in Wales (born between 1991 and 1998) with depression who attended Child and Adolescent Mental Health Services. We employed an instrumental variable (IV) analysis, using regional variation in SSRI prescribing practice to estimate the causal effect of cumulative SSRI treatment on psychosis risk, applying two‐stage least squares and IV probit models.
Results
Our cohort included n = 6615 individuals with adolescent depression. We found no evidence that cumulative SSRI prescription influenced the psychosis risk across intervention windows (1 year: β : 0.114, CI: −0.049, 0.276; 2 years: β 0.062, CI: −0.114, 0.239; 3 years: β 0.021, CI: −0.125, 0.168).
Conclusion
This quasi‐experimental study found no evidence of a causal relationship between SSRI treatment in adolescence and later psychosis risk. Our findings do not support the hypothesis that SSRI treatment of CMDs in adolescence prevents later psychosis.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Psychiatry, Institute for Neuroscience and Cardiovascular Research, University of Edinburgh, Edinburgh, UK.
- Discipline of Psychiatry and Mental Health, University of New South Wales, Sydney, New South Wales, Australia.
- School of Medicine, University College Dublin, Dublin, Ireland.
- Faculty of Medicine, University of Oulu, Oulu, Finland.
- St John of God Hospitaller Services Group, Dublin, Ireland.
ORCID-Profile: Animesh Talukder
Förderung
- Department for Business, Energy and Industrial Strategy, UK Government
- Health Research Board
- Academy of Medical Sciences
Zitieren
APA
Kougianou, I., Talukder, A., Hare, K. O., Healy, C., & Kelleher, I. (2026). Selective Serotonin Reuptake Inhibitor Treatment in Adolescence and Subsequent Risk of Nonaffective Psychosis: A Quasi‐Experimental Study. Acta Psychiatrica Scandinavica, 154(2), 153-162. https://doi.org/10.1111/acps.70098
Vancouver
Kougianou I, Talukder A, Hare KO, Healy C, Kelleher I. Selective Serotonin Reuptake Inhibitor Treatment in Adolescence and Subsequent Risk of Nonaffective Psychosis: A Quasi‐Experimental Study. Acta Psychiatrica Scandinavica. 2026;154(2):153-162. doi:10.1111/acps.70098
BibTeX
@article{Kougianou2026,
author = {Kougianou, Ioanna and Talukder, Animesh and Hare, Kirstie O and Healy, Colm and Kelleher, Ian},
title = {Selective Serotonin Reuptake Inhibitor Treatment in Adolescence and Subsequent Risk of Nonaffective Psychosis: A Quasi‐Experimental Study},
journal = {Acta Psychiatrica Scandinavica},
year = {2026},
volume = {154},
number = {2},
pages = {153--162},
doi = {10.1111/acps.70098}
}
EUVIMED